Nanoallergen platform for detection of platin drug allergies

Peter E Deak; Baksun Kim; Ather Adnan; Marina Labella; Leticia De Las Vecillas; Mariana Castells; Basar Bilgicer

doi:10.1016/j.jaci.2019.01.010

Nanoallergen platform for detection of platin drug allergies

J Allergy Clin Immunol. 2019 May;143(5):1957-1960.e12. doi: 10.1016/j.jaci.2019.01.010. Epub 2019 Jan 23.

Authors

Peter E Deak¹, Baksun Kim¹, Ather Adnan², Marina Labella², Leticia De Las Vecillas³, Mariana Castells², Basar Bilgicer⁴

Affiliations

¹ Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Ind.
² Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
³ Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Department of Allergy, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
⁴ Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Ind; Advanced Diagnostics and Therapeutics, University of Notre Dame, Notre Dame, Ind; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Ind. Electronic address: bbilgicer@nd.edu.

Abstract

In this study, we validated a novel nanoparticle based in vitro diagnostic technique for drug allergies to two common platinum-based chemotherapeutics, oxaliplatin and carboplatin.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Allergens / immunology*
Antineoplastic Agents / adverse effects*
Carboplatin / adverse effects*
Cell Line
Desensitization, Immunologic
Drug Hypersensitivity / diagnosis*
Drug Hypersensitivity / etiology
Drug Hypersensitivity / immunology
Drug Hypersensitivity / therapy
Female
Humans
Immunoglobulin E / immunology
Liposomes
Male
Middle Aged
Nanoparticles*
Oxaliplatin / adverse effects*
Skin Tests

Substances

Allergens
Antineoplastic Agents
Liposomes
Oxaliplatin
Immunoglobulin E
Carboplatin

Grants and funding

R01 AI108884/AI/NIAID NIH HHS/United States